|
Improving Access to
Breast Cancer Clinical Trials
Treatment Drugs:
Edotecarin
in Treating Women With Locally Advanced or Metastatic Breast Cancer
That Has Not Responded to Anthracycline and Taxane Chemotherapy
Conditions: recurrent breast cancer; stage IIIA breast cancer; stage
IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer
Amonafide
in Treating Women With Metastatic Breast Cancer That Has Progressed
After Previous Chemotherapy
Conditions: stage IV breast cancer; recurrent breast cancer
Goserelin
in Preventing Ovarian Failure in Women Receiving Adjuvant Chemotherapy
for Breast Cancer
Conditions: Breast Cancer; Hot Flashes; menopausal symptoms; Osteoporosis;
sexual dysfunction and infertility
Docetaxel
in Treating Older Patients With Metastatic Breast or Lung Cancer
Conditions: stage IV breast cancer; stage IV non-small cell lung
cancer; Male Breast Cancer; recurrent non-small cell lung cancer;
recurrent breast cancer
Trastuzumab
and Gefitinib in Treating Patients With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer; Male
Breast Cancer
Celecoxib
in Treating Women With Metastatic or Recurrent Breast Cancer
Conditions: recurrent breast cancer; stage IV breast cancer
Zoledronate,
Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving
Adjuvant Chemotherapy for Breast Cancer
Conditions: Breast Cancer; Osteoporosis
Doxorubicin,
Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating
Women With Inflammatory or Locally Advanced Breast Cancer
Conditions: stage II breast cancer; stage IIIA breast cancer; stage
IIIB breast cancer; stage IIIC breast cancer; inflammatory breast
cancer
Trastuzumab,
Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage
IV Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
Paclitaxel
With or Without Bevacizumab in Treating Patients With Locally Recurrent
or Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer; Male
Breast Cancer
Evaluation
of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast
Cancer Patients Receiving Weekly Paclitaxel
Conditions: Breast Neoplasms; Breast Diseases; Metastases, Neoplasm
Medroxyprogesterone
in Treating Women With Breast Cancer
Conditions: Endometrial Cancer; stage I breast cancer; stage II
breast cancer; intraductal breast carcinoma; lobular breast carcinoma
in situ; ...
Clinical
research study of an investigational cancer drug in women with metastatic
breast cancer whose cancer has gotten worse after anthracycline
and taxane therapy
Conditions: Breast Neoplasms; Neoplasms Metastasis
Breast
Neoplasms Study
Condition: Breast Neoplasms
Pentostatin
in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Conditions: Breast Cancer; Endocrine Cancer; female reproductive
cancer; Graft Versus Host Disease; hematopoietic and lymphoid cancer;
Neuroblastoma
Capecitabine
Combined with Cisplatin in Treating Patients With Locally Advanced
or Metastatic Solid Tumors
Conditions: Breast Cancer; Gastrointestinal Cancer; Head and Neck
Cancer; thorax and respiratory cancer; unclassified and other cancer
Vaccine
Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Conditions: Breast Cancer; Male Breast Cancer
Erlotinib
and Bevacizumab in Treating Women With Stage IV Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer; Male
Breast Cancer
Liposomal
Doxorubicin and Trastuzumab in Treating Women With Advanced Breast
Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
The
Evaluation of the Efficacy and Tolerability of FASLODEX (fulvestrant)
and AROMASIN (exemestane) in Hormone Receptor Positive Postmenopausal
Women with Advanced Breast Cancer.
Conditions: Breast Neoplasms; Metastases, Neoplasm
Anastrozole
and Gefitinib Compared With Fulvestrant and Gefitinib in Treating
Postmenopausal Women With Recurrent or Metastatic Breast Cancer
Conditions: recurrent breast cancer; stage IV breast cancer
Adjuvant
Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients
With Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer; stage
IIIA breast cancer; stage IIIC breast cancer; Male Breast Cancer
Zoledronate
in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy
After Surgery For Early Stage Breast Cancer
Conditions: Osteoporosis; stage I breast cancer; stage II breast
cancer
Combination
Chemotherapy With or Without Colony-stimulating Factors in Treating
Women With Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer; stage
IIIA breast cancer; stage IIIB breast cancer
Combination
Chemotherapy in Treating Women With Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer
Combination
Chemotherapy With or Without Trastuzumab in Treating Women With
Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer; stage
IIIA breast cancer
Anastrozole
Compared With Tamoxifen After Lumpectomy in Treating Postmenopausal
Women With Ductal Carcinoma in Situ
Conditions: breast cancer in situ; intraductal breast carcinoma
Docetaxel
in Treating Older Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
Radiation
Therapy With or Without Optional Tamoxifen in Treating Women With
Ductal Carcinoma in Situ
Conditions: breast cancer in situ; intraductal breast carcinoma
Celecoxib
in Treating Postmenopausal Women Who Are Undergoing Surgery for
Invasive Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer; stage
IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast
cancer
Exemestane
Compared With Anastrozole, With or Without Celecoxib, in Treating
Postmenopausal Women After Surgery for Primary Breast Cancer
Conditions: stage IIIA breast cancer; stage I breast cancer; stage
II breast cancer
Tipifarnib,
Doxorubicin, and Cyclophosphamide in Treating Women With Locally
Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer; inflammatory breast cancer
Trastuzumab,
Ixabepilone, and Carboplatin in Treating Patients With HER2/neu-Positive
Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer; Male
Breast Cancer
Anastrozole
With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal
Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
Doxorubicin
and Cyclophosphamide Plus Paclitxael With or Without Trastuzumab
in Treating Women With Node-Positive Breast Cancer That Overexpresses
HER2
Conditions: stage II breast cancer; stage IIIA breast cancer
Phase
II trial of oral study drug in patients with advanced metastatic
breast cancer who have experienced failure of an anthracycline,
a taxane, and capecitabine
Conditions: Breast Cancer; Neoplasm Metastasis
Neoadjuvant
or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating
Women With Stage I, Stage II, or Stage III Breast Cancer
Conditions: stage I breast cancer; stage II breast cancer; stage
IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast
cancer; ...
Trastuzumab
and Ixabepilone in Treating Women With HER2-Positive Metastatic
Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
Risedronate
Sodium on Bone in Postmenopausal Women with Hormone-Receptor-Positive
Early Breast Cancer
Condition: Breast Cancer
Combination
Chemotherapy With or Without Trastuzumab in Treating Women With
Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
Comparison
of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and
ZD1839 (IRESSA ) 250 mg combination in patients with metastatic
breast cancer and estrogen receptor (ER) and/or progesterone (PR)
positive tumours
Condition: Breast Neoplasms
GW572016
For Treatment Of Refractory Metastatic Breast Cancer
Condition: Metastatic breast cancer
Study
Comparing GW572016 And Letrozole Versus Letrozole In Subjects With
Advanced Or Metastatic Breast Cancer
Condition: Metastatic breast cancer
Study
of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast
Cancer
Condition: Breast Cancer
Use
of Neulasta with chemotherapy in elderly patients with cancer
Jamaica; Biomedical Research Alliance of New York
A
phase 2 randomized open-label study of letrozole in combination
with two dose levels and schedules of oral CCI-779, or letrozole
alone, in postmenopausal women with locally advanced or metastatic
breast cancer
Brooklyn; Hemocare, P.C., Great Neck; Arena Oncology Associates
Breast
Cancer- Metastatic in Postmenopausal Women
Jamaica; Biomedical Research Alliance of New York
Breast
Cancer- Metastatic
Jamaica; Biomedical Research Alliance of New York
Study
for patients with metastatic breast cancer
New York; Columbia-Presbyterian Medical Center
A
Phase I trial to determine the safety of Desoriton, a LH-RH antagonist,
alone with low dose hormone replacement to cause regression of Breast
Tissue Density in young women
New York; Columbia University Cancer Center
Breast
Cancer- Metastatic
Jamaica; Biomedical Research Alliance of New York
Breast
Cancer- Advanced or metastatic
Manhasset; Biomedical Research Alliance of New York
The
purpose of this study is to gather more information on the efficacy
of ZD1839 given with Tamoxifen® in patients 18 or older with
metastatic breast cancer
New York; Research Site, Staten Island; Research Site
Gemcitabine
plus Docetaxel or Docetaxel plus Capecitabine in Metastatic Breast
Cancer
Various Cities; Research Site
GW572016,
An Oral Drug For Women With Refractory Metastatic Breast Cancer
After First-line Or Second-line Herceptin
White Plains; Study Site
Phase
II trial of oral study drug in patients with advanced metastatic
breast cancer who have experienced failure of an anthracycline,
a taxane, and capecitabine.
New York; Research Center
Do
you want to join our Cancer Treatment Improvement Study?
Various Cities; Inflexxion, Inc.
Phase
II Study of Trastuzumab (Herceptin®), Ixabepilone, and Carboplatin
in Patients With HER2/neu-Positive Metastatic Breast Cancer
Phase
I Study of Erlotinib in Patients With Solid Tumors and Hepatic or
Renal Dysfunction
Phase
III Randomized Study of Whole Breast Radiotherapy Versus Observation
With or Without Optional Tamoxifen in Women With Good-Risk Ductal
Carcinoma In Situ of the Breast
Phase
III Randomized Study of Doxorubicin and Cyclophosphamide Followed
By Paclitaxel With or Without Trastuzumab (Herceptin) in Women With
Node
Phase
III Randomized Study of Medroxyprogesterone Acetate Versus Observation
for Prevention of Endometrial Pathology in Postmenopausal Women
With Breast Cancer Treated With Adjuvant Tamoxifen
Phase
III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, and
Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim (G-CSF),
and Epoetin Alfa Followed By Paclitaxel Versus Cyclophosphamide
and Doxorubicin Followed By Paclitaxel in Premenopausal or Early
Postmenopausal Women With Previously Resected Node Positive or High-Risk
Node Negative Stage I-IIIB Breast Cancer
Phase
III Randomized Study of Standard Neoadjuvant Doxorubicin and Cyclophosphamide
Followed By Weekly Paclitaxel Versus Weekly Doxorubicin and Daily
Oral Cyclophosphamide With Filgrastim (G-CSF) Followed By Weekly
Paclitaxel in Women With Inflammatory or Locally Advanced Breast
Cancer
Phase
III Randomized Study of Adjuvant Chemotherapy Comprising Standard
Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin
and Cyclophosphamide (AC) Versus Oral Capecitabine in Elderly Women
With Operable Adenocarcinoma of the Breast
Phase
III Randomized Study of Adjuvant Cyclophosphamide and Doxorubicin
Versus Paclitaxel in Women With High-Risk Node-Negative Breast Cancer
Phase
III Randomized Study of Zoledronate for the Prevention of Bone Loss
in Premenopausal Women Receiving Adjuvant Chemotherapy For Early
Stage Breast Cancer
Phase
I/II Study of Doxorubicin HCl Liposome and Trastuzumab (Herceptin)
in Women With Advanced HER-2/Neu-Overexpressing Breast Cancer
Phase
II Pilot Study of Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide,
and Paclitaxel in Women With High-Risk Stage I-III Breast Cancer
Phase
II Study of GW572016 in Women With Stage IIIB or IV Breast Cancer
Phase
II Pilot Study of Trastuzumab (Herceptin), Docetaxel, and Vinorelbine
With Filgrastim (G-CSF) Support in Women With HER2-Positive Stage
IV Breast Cancer
Phase
II Study of ABI-007, Carboplatin, and Trastuzumab (Herceptin®)
in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer
Phase
II Study of Tipifarnib and Fulvestrant as Second-Line Therapy in
Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally
Advanced or Metastatic Breast Cancer With Progressive Disease After
Prior First-Line Endocrine Therapy
Phase
II Study of Trastuzumab (Herceptin®) and Ixabepilone (BMS-247550)
in Women With HER2-Positive Metastatic Breast Cancer
Phase
II trial of oral study drug in patients with advanced metastatic
breast cancer who have experienced failure of an anthracycline,
a taxane, and capecitabine
Comparison
of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and
ZD1839 (IRESSA™) 250 mg combination in patients with metastatic
breast cancer and estrogen receptor (ER) and/or progesterone (PR)
positive tumours
Phase
II Study of Trastuzumab (Herceptin®), Ixabepilone, and Carboplatin
in Patients With HER2/neu-Positive Metastatic Breast Cancer
Phase
II Study of Capecitabine and Tipifarnib in Women With Taxane-Resistant
Metastatic Breast Cancer
Phase
I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Phase
II Study of Intravenous Edotecarin (PHA-782615) in Patients with
Anthracycline- and Taxane-Resistant Metastatic Breast Cancer
Phase
II Study of OSI-774 & Bevacizumab in Patients with Stage IV
Breast Cancer
A
Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007)
and Carboplatin with Herceptin for Advanced HER-2-Positive Breast
Cancer
Phase
III Randomized Trial of Post-Mastectomy Radiotherapy in Stage II
Breast Cancer in Women with One to Three Positive Axillary Nodes
Phase
III Trial of Observation with or without Tamoxifen vs. Radiation
Therapy with or without Tamoxifen for Duct Carcinoma In-Situ (DCIS)
Phase
I Study of COX-2 Inhibition and Aromatase Activity in Breast Cancer
Effect
of Short-Term Preoperative Anastrozole Use on Breast Cancer Cells
Phase
III Study of Standard Adjuvant Chemotherapy versus Capecitabine
in Women 65 Years & Older with Early-Stage Breast Cancer
Phase
III Trial of Zoledronic Acid (Zometa) to Prevent Bone Loss in Patients
with Localized Breast Cancer Who Have Chemotherapy-Induced Ovarian
Failure
Pilot
Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel
for Women with Early Breast Cancer
Cytologic
Analysis of Ductal Lavage Specimens
Source: http://www.cancer.gov/ClinicalTrials/,
http://www.centerwatch.org,
http://www.Clinicaltrials.gov
If you are
interested in participating in a Breast Cancer Clinical Trial call
CDN at: (212) 382-0699, ext. 227.
Treatment
Chemotherapy
Homeopathic
Lymph Node Removal
Other Treatments: Pharmaceutical
Radiation Therapy
Treatment Drugs
Prevention
& Screening & Diagnostic
Imaging
Mammography
Prevention of Breast Cancer
Postmenopausal/ Older Women Patients
Genetics
Genetic trials
Quality
of Life/ Supportive Care
Support
Groups for Heterosexual Women with Breast Cancer & Lesbian Women
with Breast Cancer
|
